Computer-Based Design of an HLA-Haplotype and HIV-Clade Independent Cytotoxic T-Lymphocyte (CTL) Assay for Monitoring HIV-Specific Immunity

Table 1 Main characteristics of HIV-infected patients enrolled in the study

					At Enrollment				1 Month After HAART Interruption
Patient	Sex	Age	Race	HAART	CD4 (N/ µ l)	CD8 (N/ µ l)	Viral Load (copies/ml)	Anti-GAG Peptides CTL (N precursors/ml)	CD4 (N/ µ l)	CD8 (N/ µ l)	Viral Load (copies/ml)	Anti-GAG Peptides CTL (N precursors/ml)
C01	F	37	Caucasian	Yes	878	1153	<50	922	644	1342	2900	805
C03	F	36	Caucasian	Yes	795	559	<50	727	678	1724	170000	7068
C04	M	47	Caucasian	Yes	788	1508	<50	452	347	2597	670000	2619
C05	F	26	Caucasian	Yes	759	1427	<50	3710	894	1995	300	7182
C08	F	50	Caucasian	Yes	501	1446	<50	864	340	2726	71000	6815
C10	F	40	Caucasian	Yes	502	651	<50	391	509	956	80	383
C11	F	38	Caucasian	Yes	512	435	<50	391	401	1505	85000	4214
C13	F	31	Caucasian	Yes	625	623	<50	141	493	705	42000	187
C15	F	30	Caucasian	Yes	622	870	<50	87	426	1683	10000	505
C16	F	34	Caucasian	Yes	601	948	<50	15831	471	701	19000	2804
C18	M	55	Caucasian	Yes	632	1392	<50	417	522	1508	57000	151
C29	M	47	Caucasian	Yes	862	1425	<50	1567	382	1444	770	2021
A66	F	35	African	Naive	1132	907	11027	1451	n.a.*	n.a.	n.a.	n.a.
A67	M	36	African	Naive	511	1142	11230	1028	n.a.	n.a.	n.a.	n.a.
A68	F	34	African	Yes	535	2153	6162	3229	n.a.	n.a.	n.a.	n.a.
A69	F	33	African	Naive	186	1458	473480	728	n.a.	n.a.	n.a.	n.a.
A70	M	42	African	Naive	174	1258	149548	1887	n.a.	n.a.	n.a.	n.a.

ISSN: 1528-3658